Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Change in Account Payables (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Change in Account Payables readings, the most recent being $1.2 million for Q4 2022.

  • On a quarterly basis, Change in Account Payables fell 33.32% to $1.2 million in Q4 2022 year-over-year; TTM through Dec 2022 was $3.4 million, a 80.64% increase, with the full-year FY2025 number at $188727.9, up 124.27% from a year prior.
  • Change in Account Payables hit $1.2 million in Q4 2022 for Cardiol Therapeutics, up from $2612.3 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.9 million in Q4 2020 to a low of -$283018.6 in Q3 2021.
  • Median Change in Account Payables over the past 3 years was $570881.5 (2022), compared with a mean of $802860.1.
  • The widest YoY moves for Change in Account Payables: up 1125.24% in 2022, down 33.32% in 2022.
  • Cardiol Therapeutics' Change in Account Payables stood at $1.9 million in 2020, then fell by 1.83% to $1.9 million in 2021, then plummeted by 33.32% to $1.2 million in 2022.
  • The last three reported values for Change in Account Payables were $1.2 million (Q4 2022), $2612.3 (Q3 2022), and $1.6 million (Q2 2022) per Business Quant data.